Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATRA liposomes
- Development stage
- Unknown
- Lead developer
- HighField Biopharmaceuticals
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
ATRA liposomes are a formulation of all-trans retinoic acid (ATRA) encapsulated within a lipid bilayer (liposome), designed to improve the pharmacokinetic profile and therapeutic efficacy of ATRA. This delivery system enhances drug stability, prolongs plasma exposure, and reduces toxicity compared to oral or non-liposomal forms. Mechanistically, ATRA is a potent agonist of the retinoic acid receptor beta (RARβ2), promoting differentiation in malignant cells—most notably in acute promyelocytic leukemia (APL)—and modulating immune responses by targeting myeloid-derived suppressor cells and enhancing CD8+ T cell activity. Liposomal encapsulation allows for improved tumor targeting and has shown promise in both hematologic malignancies like APL and solid tumors such as glioma and brain cancer[1][2][5][7].
- Other names
- liposome suspension containing encapsulated ATRAliposomal all-trans retinoic acid
02
Targets
RARA (Retinoic acid receptor alpha)RARG (Retinoic acid receptor gamma)RARB (Retinoic acid receptor beta)
Beyond the preview
Go deeper on ATRA liposomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATRA liposomes.